Ocugen, Inc.
No SEC Form 4 filings for $OCGN in the last 30 days.
See all $OCGN insider activity →Ocugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in a global Phase 3 trial for OCU410, a gene therapy candidate for dry age-related macular degeneration. The FDA granted OCU410 RMAT designation, potentially accelerating development. Ocugen aims to offer a one-time treatment for the condition, with no approved treatments outside the U.S. and limited options in the U.S.
Ocugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in its global Phase 3 trial for OCU410, a gene therapy for dry age-related macular degeneration. The FDA granted RMAT designation to OCU410, potentially accelerating development. The trial follows a successful End-of-Phase 2 meeting with the FDA.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry ag
Over the past 7 days, alphai's AI scored 2 news stories mentioning OCGN (Ocugen, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent OCGN coverage spans financial news, technology and earnings.
Positive trial initiation and RMAT status may boost stock as investors anticipate pivotal data.
Positive catalyst may boost OCGN stock as trial progresses.
Near-term catalysts shift toward Phase 3 initiation and upcoming topline readouts, funded by new capital and supported by FDA designations.
The deal terms improve Ocugen’s near-term cash visibility and create a new regional commercialization pathway for OCU400, supporting valuation and sentiment.
Insider buying is a modest bullish signal, but the disclosed transaction size is small versus typical institutional flows and is unlikely to drive a sustained repricing alone.
alphai scores every news story that mentions OCGN with an AI model for sentiment and relevance, and aggregates insider trades from Ocugen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in a global Phase 3 trial for OCU410, a gene therapy candidate for dry age-related macular degeneration. The FDA granted OCU410 RMAT designation, potentially accelerating development. Ocugen aims to offer a one-time treatment for the condition, with no approved treatments outside the U.S. and limited options in the U.S.
2 min readOcugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in its global Phase 3 trial for OCU410, a gene therapy for dry age-related macular degeneration. The FDA granted RMAT designation to OCU410, potentially accelerating development. The trial follows a successful End-of-Phase 2 meeting with the FDA.
1 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Second Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry ag
6 min readOcugen (NASDAQ: OCGN) said it signed a binding term sheet to negotiate an exclusive license for its OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa with Roots Pharmaceutical and Al-Dhow International Holding. Ocugen expects up to $4 million in upfront and near-term milestones, up to $255 million in sales milestones, and 22% royalties on net sales. Ocugen will manufacture OCU400, with a definitive deal expected within 90 days.
4 min readJohnson-Greene Treerita Essalima (Chief Financial Officer) purchased 21,000 shares of Ocugen, Inc. (OCGN) at $1.23 on 2026-06-15.
2 min readOcugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001372299 0001372299 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report
3 min readOcugen, Inc. reported Q1 EPS of (6c) against a consensus of (5c) and revenue of $1.53M, significantly exceeding expectations. The company announced progress in its late-stage clinical programs, including completed enrollment for two trials and plans for BLA submissions for retinitis pigmentosa and OCU410ST, as well as a registration trial for dry AMD. Ocugen also revealed a proposed private offering of $115M in convertible senior notes.
3 min readThis article provides financial information for Ocugen Inc (A2PSZH) on the Lang & Schwarz Exchange, specifically focusing on the number of shareholders. It appears to be a stub or data reference page from TradingView, offering an overview of the company's financials without detailed analytical content in the provided text. The page highlights market data and general company information, indicating a closed market status.
1 min readOcugen has announced an amended preliminary proxy statement for its Annual Meeting on June 11, 2026, including a proposal for a reverse stock split ranging from 1:2 to 1:8. The company also provided updates on its clinical programs, with OCU400 Phase 3 topline data expected in Q1 2027 and positive Phase 2 results for OCU410. Recent financing activities, totaling $37.5 million, are projected to extend the cash runway into Q1 2027.
4 min readMillennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G disclosing their shared beneficial ownership of 17,074,584 shares of Ocugen, Inc. common stock, representing 5.2% of the class. The filing indicates shared voting and dispositive power over these shares. The Schedule 13G was signed on April 13, 2026, and lists the CUSIP number as 67577C105.
2 min read
